%PDF-1.4
%
121 0 obj
<>
endobj
118 0 obj
<>
endobj
242 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-08T10:27:12Z
2024-03-28T06:18:03-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T06:18:03-07:00
application/pdf
Heather
2004-588.sept
uuid:1c8bfc44-1dd2-11b2-0a00-5508277d8900
uuid:1c8bfc47-1dd2-11b2-0a00-d30000000000
endstream
endobj
105 0 obj
<>
endobj
107 0 obj
<>
endobj
106 0 obj
<>
endobj
108 0 obj
<>
endobj
98 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
243 0 obj
[249 0 R]
endobj
244 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 55.968 737.5293 Tm
[(38.)-875 (Grandvaux N, tenOever BR, Servant MJ, Hiscott J. )18 (The interferon)]TJ
2.175 -1.25 Td
(antiviral response: from viral invasion to evasion. Curr Opin Infect)Tj
0 Tc 0 -1.25 TD
(Dis 2002;15:259-67.)Tj
-2.175 -1.25 Td
[(39.)-875 (T)70 (aki S. )18 (T)70 (ype I interferons and autoimmunity: lessons from the )]TJ
2.175 -1.25 Td
(clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev)Tj
0 Tw T*
(2002;13:379-91.)Tj
0.0249 Tw -2.175 -1.25 Td
[(40.)-875 (Blanco P)111 (, Palucka )55 (AK, Gill M, Pascual )18 (V)129 (, Banchereau J. Induction)]TJ
2.175 -1.25 Td
[(of dendritic cell dif)18 (ferentiation by IFN-alpha in systemic lupus )]TJ
T*
(erythematosus. Science 2001;294:1540-3.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(41.)-875 (Bennett L, Palucka )55 (AK, )55 (Arce E, et al. Interferon and granulopoiesis)]TJ
0 Tc 2.175 -1.25 Td
(signatures in systemic lupus erythematosus blood. J Exp Med)Tj
0 Tw T*
[(2003;197:71)37 (1-23.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(42.)-875 (Pascual )18 (V)129 (, Banchereau J, Palucka )55 (AK. )18 (The central role of dendritic)]TJ
2.175 -1.25 Td
(cells and interferon-alpha in SLE. Curr Opin Rheumatol)Tj
0 Tw T*
(2003;15:548-56.)Tj
0.0249 Tw -2.175 -1.25 Td
[(43.)-875 (Swain )55 (A, Cof)18 (fin JM. Polyadenylation at correct sites in genome)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(RNA)-220 (is not required for retrovirus replication or genome )]TJ
0 Tc T*
[(encapsidation. J )18 (V)60 (irol 1989;63:3301-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(44.)-875 (Swain )55 (A, Cof)18 (fin JM. Mechanism of transduction by retroviruses.)]TJ
0 Tc 2.175 -1.25 Td
(Science 1992;255:841-5.)Tj
-2.175 -1.25 Td
[(45.)-875 (Hasuike S, Miura K, Miyoshi O, et al. Isolation and localization of)]TJ
2.175 -1.25 Td
(an IDDMK1,2-22-related human endogenous retroviral gene, and)Tj
T*
[(identification of a CA)-220 (repeat marker at its locus. J Hum Genet)]TJ
0 Tw T*
(1999;44:343-7.)Tj
0.02499 Tw -2.175 -1.25 Td
[(46.)-875 (T)70 (akemura S, Braun )55 (A, Crowson C, et al. L)55 (ymphoid neogenesis in)]TJ
2.175 -1.25 Td
(rheumatoid synovitis. J Immunol 2001;167:1072-80.)Tj
-2.175 -1.25 Td
[(47.)-875 (W)80 (eyand CM, Goronzy JJ. Ectopic germinal center formation in)]TJ
2.175 -1.25 Td
[(rheumatoid synovitis. )55 (Ann NY)-183 (Acad Sci 2003;987:140-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(48.)-875 (Geisse S, Scheidereit C, )18 (W)80 (estphal HM, Hynes NE, Groner B, Beato)]TJ
2.175 -1.25 Td
[(M. Glucocorticoid receptors recognize DNA)-220 (sequences in and)]TJ
T*
(around murine mammary tumour virus DNA. EMBO )Tj
0 Tc T*
(J 1982;1:1613-9.)Tj
-2.175 -1.25 Td
[(49.)-875 (T)70 (ovar Sepulvede )18 (V)129 (A, Berdel B, Cof)18 (fin JM, Reuss FU. Mouse )]TJ
2.175 -1.25 Td
(mammary tumor virus superantigen expression is reduced by )Tj
T*
[(glucocorticoid treatment. )18 (V)60 (irology 2000;275:98-106.)]TJ
30.825 42.5 Td
[(50.)-875 (Shodell M, Shah K, Siegal FP)111 (. Circulating human plasmacytoid)]TJ
2.175 -1.25 Td
(dendritic cells are highly sensitive to corticosteroid administration.)Tj
T*
(Lupus 2003;12:222-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(51.)-875 (Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL,)]TJ
0 Tc 2.175 -1.25 Td
[(Notkins )55 (AL. Immune interferon in the circulation of patients with)]TJ
T*
(autoimmune disease. N Engl J Med 1979;301:5-8.)Tj
-2.175 -1.25 Td
[(52.)-875 (Preble OT)74 (, Black RJ, Friedman RM, Klippel JH, )18 (V)60 (ilcek J. Systemic)]TJ
2.175 -1.25 Td
(lupus erythematosus: presence in human serum of an unusual )Tj
T*
(acid-labile leukocyte interferon. Science 1982;216:429-31.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(53.)-875 (V)111 (allin H, Perers )55 (A, )55 (Alm GV)129 (, Ronnblom L. )55 (Anti-double-stranded)]TJ
0 Tc 2.175 -1.25 Td
[(DNA)-220 (antibodies and immunostimulatory plasmid DNA)-220 (in )]TJ
T*
(combination mimic the endogenous IFN-alpha inducer in systemic)Tj
T*
(lupus erythematosus. J Immunol 1999;163:6306-13.)Tj
-2.175 -1.25 Td
[(54.)-875 (Bengtsson )55 (AA, Sturfelt G, )18 (T)35 (ruedsson L, et al. )55 (Activation of type I)]TJ
-0.00011 Tc 2.175 -1.25 Td
(interferon system in systemic lupus erythematosus correlates with)Tj
0 Tc T*
(disease activity but not with antiretroviral antibodies. Lupus)Tj
0 Tw T*
(2000;9:664-71.)Tj
0.0249 Tw -2.175 -1.25 Td
[(55.)-875 (Lanza L, Scudeletti M, Monaco E, et al. Possible dif)18 (ferences in the)]TJ
2.175 -1.25 Td
[(mechanism\(s\) of action of dif)18 (ferent glucocorticoid hormone )]TJ
T*
[(compounds. )55 (Ann NY)-183 (Acad Sci 1999;876:193-7.)]TJ
-2.175 -1.25 Td
[(56.)-875 (Lanza L, Scudeletti M, Puppo F)80 (, et al. Prednisone increases )]TJ
2.175 -1.25 Td
[(apoptosis in in vitro activated human peripheral blood )18 (T)]TJ
T*
(lymphocytes. Clin Exp Immunol 1996;103:482-90.)Tj
-2.175 -1.25 Td
[(57.)-875 (Scudeletti M, Lanza L, Monaco E, et al. Immune regulatory )]TJ
-0.00011 Tc 2.175 -1.25 Td
(properties of corticosteroids: prednisone induces apoptosis of)Tj
0 Tc T*
[(human )18 (T)-257 (lymphocytes following the CD3 down-regulation. )55 (Ann)]TJ
T*
[(NY)-183 (Acad Sci 1999;876:164-79.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(58.)-875 (Blomber)18 (g S, Eloranta ML, Magnusson M, )55 (Alm GV)129 (, Ronnblom L.)]TJ
2.175 -1.25 Td
(Expression of the markers BDCA-2 and BDCA-4 and production)Tj
0 Tc T*
(of interferon-alpha by plasmacytoid dendritic cells in systemic)Tj
T*
[(lupus erythematosus. )55 (Arthritis Rheum 2003;48:2524-32.)]TJ
-2.175 -1.25 Td
[(59.)-875 (Dzionek )55 (A, Sohma )37 (Y)129 (, Nagafune J, et al. BDCA-2, a novel )]TJ
2.175 -1.25 Td
(plasmacytoid dendritic cell-specific type II C-type lectin, mediates)Tj
T*
(antigen capture and is a potent inhibitor of interferon alpha/beta)Tj
T*
(induction. J Exp Med 2001;194:1823-34.)Tj
ET
/CS0 CS 0 0 0 1 SCN
52.97 77 m
557.97 77 l
S
0 0 0 0 scn
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT1 1 Tf
0 Tw 8 0 0 8 540.968 56.9344 Tm
(1831)Tj
ET
0 0 0 0 scn
/GS0 gs
104.13 81.68 407.5 -10.83 re
f*
0.5 w
104.13 81.68 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.02499 Tw 8 0 0 8 54.032 57.3695 Tm
[(Sicat, et al: HER)18 (V)55 (-K18 superantigen)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
165 0 obj
<>
endobj
248 0 obj
<>
endobj
132 0 obj
<>
endobj
125 0 obj
<>
endobj
124 0 obj
<>
endobj
157 0 obj
<>stream
HV PWn9g[&x=
fЈӃJ
EQ)M4Y-7A&PZkxd-k$1e:_x%U[;u@ Z(țRz_fjU*C; DUQu~v(ھeS]bX@1/-ۈp *W`N("V }NgyEՒP 043rxoIeX||_WQrz>P|V.X\eݦem{墒/xuLӪ2qZ>(5V`2
[Rmh8QwpKш^HAơސ،UXb3v'6"bTs2Vn ^RQc4LB>=^ T
Y0Fś |ia^rJωǓp>*sEpc$FkJiv?,טE 1pOLVOkdDaø3P:md_c9YW'
{>gg.@h!BE//W⢌Ґ%%U,PO͚'P*
֧"ϲ32fq1sfwXc>
ۍyI7ɡq,E$GHH.Vm8'&j\Ԋ
QGħ++LZ^7OJ8Yj:MݥEhV2@u"ZfmEG`GRձϑǛ6QRcoYCb>]:NpxPYn)/3eFE(L1KrP&j:&v=.n;l&e'4v&Wsx*d\%ߖM}CIr;}GS0> ?r8ƛ5Eb7$F>װ|Z-:tg9='ab<bݷO\i)z.9+ޣ{bB|\ؘ訮]:w!}PG*R cxu3k.[6|TRxMg}LtӟtӳgVOcOPW1tD7i^mfKp=.VB
N'wl^cT=lkv44uގl"˷<1lڔ$̛XɎw:]i*2f0FS۶#,3$9vXI;_b7T|R#یy9hYfFS&J9,͚ѭז|k)yIgL+X[(1<;W7ÌQF5Թ7.dKͣ'NsDQNIKͭw{Jk]>ɒ5FFg+Zgy̤U6EfaE: L%W Q&),3,lTK4t`j|ma/f?0?ZfJ
{M6